US Patent

US8349892 — Solid formulations of prostacyclin analogs

Formulation · Assigned to United Therapeutics Corp · Expires 2031-01-22 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid formulations of prostacyclin analogs, such as treprostinil diolamine, packaged with a desiccant to maintain moderate moisture levels.

USPTO Abstract

Moderate moisture levels, such as greater than 3% but no greater than 7%, may be beneficial for solid formulations of certain prostacyclin analogs. Accordingly, a solid formulation containing a prostacyclin analog may be packaged inside a pharmaceutical packaging with such amount of a desiccant or a drying agent that after the storage the solid formulation may have a moderate level of moisture in it.

Drugs covered by this patent

treprostinil-diolamine (TREPROSTINIL DIOLAMINE)

Patent Metadata

Patent number: US8349892
Jurisdiction: US
Classification: Formulation
Expires: 2031-01-22
Drug substance claim: No
Drug product claim: Yes
Assignee: United Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.